文献速递临床试验与 GCP

锂剂预防乳腺癌患者化疗所致周围神经病变:安慰剂对照随机临床试验

Lithium and preventing chemotherapy-induced peripheral neuropathy in breast cancer patients: a placebo-controlled randomized clinical trial.
PubMed 文献 · Trials · 2021-11-24

该双盲安慰剂对照随机临床试验纳入36例接受紫杉类和铂类化疗的乳腺癌患者,随机分为两组,每周期化疗前1天起每日服用锂剂300 mg或安慰剂共5天。结果显示两组所有肌电图-神经传导速度指标在9个月内均显著变化(P < 0.001),但时间与分组交互效应不显著;症状随时间显著变化(P < 0.001),组间差异无统计学意义(P=0.352)。作者认为300 mg锂剂每日一次连用5天可能不能有效预防化疗所致周围神经病变。

要点

  • 在36例接受紫杉类和铂类化疗的乳腺癌患者中,锂剂300 mg每日一次连用5天组与安慰剂组CIPN症状评分差异无统计学意义(P=0.352)。
  • 两组肌电图-神经传导速度指标在9个月内均显著变化(P < 0.001),但时间与分组交互效应均不显著。
  • 研究期间未发现副作用,作者建议未来在不同癌症中评估锂剂对CIPN的作用。

核心结论

  • 300 mg锂剂每日一次连用5天可能不能有效预防乳腺癌患者的化疗所致周围神经病变。
  • 作者建议未来研究在不同癌症中评估锂剂对化疗所致周围神经病变的作用。

研究设计与样本

  • 双盲安慰剂对照随机临床试验,采用区组随机化将36例乳腺癌患者分为两组,每组18例。
  • 两组在每个化疗周期均每日服用片剂(安慰剂或锂剂300 mg)共5天,于化疗开始前1天开始服药。
  • 在首次化疗前、治疗后3个月和9个月进行肌电图和神经传导速度检测,并通过检查记录CIPN体征和症状。
  • 在9个月研究期间比较两组结局变化趋势。试验注册号:IRCT20160813029327N10,注册日期2018年5月16日。

主要发现

  • 两组神经体征和症状在开始3个月内加重,至研究第9个月改善。
  • 两组所有肌电图-神经传导速度指标在研究9个月内均显著变化(P < 0.001),但时间与分组交互效应在所有指标中均不显著。
  • 所有症状在研究期间显著变化(P < 0.001),两组间差异无统计学意义(P=0.352)。
  • 研究期间未发现副作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of some chemotherapy regimens. Lithium has been suggested for CIPN in some animal studies. We aimed to study lithium's preventive effect on CIPN in breast cancer patients treated with taxanes and platinum-based medications. METHOD: A double-blind placebo-controlled randomized clinical trial (RCT) was implemented on 36 breast cancer patients in two equal-size groups by block randomization. Participants in both groups consumed daily tablets, either placebo or lithium (300 mg), for 5 days in each course of chemotherapy. The tablets were prescribed 1 day before the start of chemotherapy. The electromyography (EMG) and nerve-conduction-velocity (NCV) tests were achieved before the first chemotherapy, 3 and 9 months after the treatment. The changes and signs or symptoms of CIPN, such as numbness, tingling, freezing, sensitivity to touch, muscle weakness, fibrillation, and knee and elbow reflex disorders, were recorded by examination. The trend of outcome changes was compared between two groups during the 9 months of study. RESULTS: In both groups, neurologic signs and symptoms were exacerbated during the first 3 months and improved up to the ninth month of study. Results showed significant changes of all EMG-NCV variables during the 9 months of research in each group (P < 0.001), but the interaction of time and group effect was not significant in none of those indices. All symptoms changed significantly over the study time (P < 0.001) without significant statistical difference between the two groups (P=0.352). No side effect was found during the study. CONCLUSION: The study showed that 300 mg lithium prescription once daily for 5 days might not effectively prevent CIPN in breast cancer patients. Evaluation of lithium effect on CIPN on different cancers in future studies is suggested. TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT20160813029327N10 . Registration date: May 16, 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Najafi S, Heidarali Z, Rajabi M, et al. Lithium and preventing chemotherapy-induced peripheral neuropathy in breast cancer patients: a placebo-controlled randomized clinical trial. Trials. 2021. PMID: 34819131. doi:10.1186/s13063-021-05800-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。